Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.

Topriceanu CC, Vissing CR, Axelsson Raja A, Day SM, Russell MW, Zahka K, Pereira AC, Colan SD, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Mestroni L, Taylor MRG, Moon JC, Captur G, Patel AR, Wilmot I, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Bundgaard H, Tahir UA, Ho CY.

Open source

DOI: 10.1161/circheartfailure.124.012393
Published: 2025-05-09
Container: Circ Heart Fail
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1161/circheartfailure.124.012393,
  title = {Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.},
  author = {Topriceanu CC and  Vissing CR and  Axelsson Raja A and  Day SM and  Russell MW and  Zahka K and  Pereira AC and  Colan SD and  Murphy AM and  Canter C and  Bach RG and  Wheeler MT and  Rossano JW and  Owens AT and  Mestroni L and  Taylor MRG and  Moon JC and  Captur G and  Patel AR and  Wilmot I and  Soslow JH and  Becker JR and  Seidman CE and  Lakdawala NK and  Bundgaard H and  Tahir UA and  Ho CY.},
  year = {2025},
  journal = {Circ Heart Fail},
  doi = {10.1161/circheartfailure.124.012393},
  url = {https://doi.org/10.1161/circheartfailure.124.012393}
}

RIS

TY  - JOUR
TI  - Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.
AU  - Topriceanu CC
AU  -  Vissing CR
AU  -  Axelsson Raja A
AU  -  Day SM
AU  -  Russell MW
AU  -  Zahka K
AU  -  Pereira AC
AU  -  Colan SD
AU  -  Murphy AM
AU  -  Canter C
AU  -  Bach RG
AU  -  Wheeler MT
AU  -  Rossano JW
AU  -  Owens AT
AU  -  Mestroni L
AU  -  Taylor MRG
AU  -  Moon JC
AU  -  Captur G
AU  -  Patel AR
AU  -  Wilmot I
AU  -  Soslow JH
AU  -  Becker JR
AU  -  Seidman CE
AU  -  Lakdawala NK
AU  -  Bundgaard H
AU  -  Tahir UA
AU  -  Ho CY.
PY  - 2025
JO  - Circ Heart Fail
DO  - 10.1161/circheartfailure.124.012393
UR  - https://doi.org/10.1161/circheartfailure.124.012393
ER  -

APA

CC, T., CR, V., A, A. R., SM, D., MW, R., K, Z., AC, P., SD, C., AM, M., C, C., RG, B., MT, W., JW, R., AT, O., L, M., MRG, T., JC, M., G, C., AR, P., I, W., JH, S., JR, B., CE, S., NK, L., H, B., UA, T., & CY., H. (2025). Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.. Circ Heart Fail. https://doi.org/10.1161/circheartfailure.124.012393

Source records

europe-pmc · retrieved 2026-09-26T17:07:26.164Z